FDA accepts Pfizer autoimmune disease drug Tofacitinib Application
Recently, the international pharmaceutical giant Pfizer said that the FDA has accepted its treatment of moderate to severe rheumatoid arthritis adult experimental drug drug Tofacitinib applications. FDA said in August 2012 is expected to be ruled on Tofacitinib, Tofacitinib is Pfizer hailed as promising as new treatments for autoimmune diseases drugs. Pfizer said it has submitted to the Japanese Ministry of Health, new drug application, and the European Medicines Agency is to review the drug. Tofacitinib is called protein tyrosine kinases (JAK) inhibitors for the treatment of rheumatoid arthritis novel oral drug that can inhibit tyrosine kinases. Enzyme in the immune system to attack the joint inflammation plays a key role.
FDA accepts Pfizer autoimmune disease drug Tofacitinib Application
ReplyDeleteRecently, the international pharmaceutical giant Pfizer said that the FDA has accepted its treatment of moderate to severe rheumatoid arthritis adult experimental drug drug Tofacitinib applications. FDA said in August 2012 is expected to be ruled on Tofacitinib, Tofacitinib is Pfizer hailed as promising as new treatments for autoimmune diseases drugs. Pfizer said it has submitted to the Japanese Ministry of Health, new drug application, and the European Medicines Agency is to review the drug. Tofacitinib is called protein tyrosine kinases (JAK) inhibitors for the treatment of rheumatoid arthritis novel oral drug that can inhibit tyrosine kinases. Enzyme in the immune system to attack the joint inflammation plays a key role.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
BS-181
SB1317
NVP-LCQ195
Roscovitine
PD 0332991
AT7519
AT7519 hydrochloride
CVT-313
LY2603618
CCT241533